Key terms

About BAX

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, and equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest BAX news

Yesterday 5:01pm ET Baxter International Announces Board Changes for 2024 Nov 18 2:55pm ET Baxter put volume heavy and directionally bearish Nov 15 12:15pm ET Baxter put volume heavy and directionally bearish Nov 11 6:50pm ET Baxter cuts quarterly dividend to 17c per share from 29c prior Nov 11 8:31am ET Baxter price target lowered to $38 from $46 at Stifel Nov 11 8:08am ET Baxter International (BAX) Gets a Buy from Stifel Nicolaus Nov 11 8:04am ET Baxter price target lowered to $45 from $46 at Evercore ISI Nov 10 6:20am ET Baxter price target lowered to $36 from $40 at Wells Fargo Nov 09 8:25am ET Baxter International: Hold Rating Amid Operational Challenges and Moderate Growth Prospects Nov 08 11:01pm ET Baxter International Reports Resilient Q3 2024 Performance Nov 08 12:01pm ET Nvidia trades on Dow for first time, Rivian reports downbeat Q3: Morning Buzz Nov 08 7:46am ET Baxter sees Q4 adjusted EPS 77c-81c, consensus 84c Nov 08 7:45am ET Baxter cuts FY24 adjusted EPS view to $2.90-$2.94 from $2.93-$3.01 Nov 08 7:40am ET Baxter reports Q3 adjusted EPS 80c, consensus 78c Nov 08 7:05am ET Options Volatility and Implied Earnings Moves Today, November 08, 2024 Nov 07 9:47am ET Unusually active option classes on open November 7th Nov 07 9:20am ET Baxter International Sells Kidney Care to Carlyle Group Oct 14 5:00am ET ICU Medical initiated with a Hold at Jefferies Oct 10 8:05am ET Jefferies Sticks to Its Hold Rating for Baxter International (BAX) Oct 10 5:31am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Masimo (MASI), Baxter International (BAX) and Merck & Company (MRK) Oct 09 9:49am ET Baxter International Addresses Hurricane Helene Production Impact Oct 08 9:05am ET Deutsche Bank Sticks to Their Hold Rating for Baxter International (BAX) Oct 01 6:21am ET Baxter price target raised to $40 from $38 at Citi Sep 30 3:10pm ET Analysts Conflicted on These Healthcare Names: Humacyte (HUMA) and Baxter International (BAX) Sep 30 8:58am ET Baxter International Responds to Hurricane Impact on Facility Sep 30 8:27am ET Baxter financial impact from Helene ‘not a big deal,’ says Morgan Stanley Sep 30 6:56am ET Hold Rating on Baxter International Amid Post-Hurricane Operational Challenges Sep 30 6:30am ET Baxter says North Cove, NC facility affected by Hurricane Helene Sep 30 5:36am ET Hurricane Impact and Operational Challenges Prompt Sell Rating for Baxter International Sep 30 5:05am ET Hold Rating on Baxter International Amidst Hurricane Helene’s Impact on Operations Sep 23 7:56am ET Baxter International: A Cautious Hold Amidst Revenue Growth and Strategic Divestitures

BAX Financials

1-year income & revenue

Key terms

BAX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

BAX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms